To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105
NCT ID: NCT06754943
Last Updated: 2025-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
60 participants
INTERVENTIONAL
2025-01-17
2025-04-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the PK, PD, Safety and Drug Tolerance of JW0302 in Healthy Volunteers
NCT05784155
To Evaluate the PK, PD, Safety and Drug Tolerance in Healthy Volunteers
NCT05433844
Single and Multiple Ascending Dose Study of JW1601 for Healthy Volunteers
NCT04018170
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants
NCT03002025
To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants
NCT01809353
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
* Treatment A: Co-administration of 1 tablet of JW0104 and 1 tablet of C2402
* Treatment B: Administration alone of 1 tablet of JW0105
Treatment A_Period 1
* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402
* Wash-out period: 21 days
* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Treatment B_Period 2
* Administration alone of 1 tablet of JW0105
* Wash-out period: 21 days
* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions
Treatment A_Period 3
* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402
* Wash-out period: 21 days
* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Treatment B_Period 4
* Administration alone of 1 tablet of JW0105
* Wash-out period: 21 days
* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions
Group 2
* Treatment A: Co-administration of 1 tablet of JW0104 and 1 tablet of C2402
* Treatment B: Administration alone of 1 tablet of JW0105
Treatment B_Period 1
* Administration alone of 1 tablet of JW0105
* Wash-out period: 21 days
* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions
Treatment A_Period 2
* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402
* Wash-out period: 21 days
* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Treatment B_Period 3
* Administration alone of 1 tablet of JW0105
* Wash-out period: 21 days
* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions
Treatment A_Period 4
* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402
* Wash-out period: 21 days
* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Treatment A_Period 1
* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402
* Wash-out period: 21 days
* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Treatment B_Period 2
* Administration alone of 1 tablet of JW0105
* Wash-out period: 21 days
* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions
Treatment A_Period 3
* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402
* Wash-out period: 21 days
* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Treatment B_Period 4
* Administration alone of 1 tablet of JW0105
* Wash-out period: 21 days
* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions
Treatment B_Period 1
* Administration alone of 1 tablet of JW0105
* Wash-out period: 21 days
* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions
Treatment A_Period 2
* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402
* Wash-out period: 21 days
* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Treatment B_Period 3
* Administration alone of 1 tablet of JW0105
* Wash-out period: 21 days
* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions
Treatment A_Period 4
* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402
* Wash-out period: 21 days
* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
19 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
JW Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sung-Dae Kwon
Role: PRINCIPAL_INVESTIGATOR
Metro Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Metro Hospital
Anyang-si, Gyeonni-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JW24102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.